Riskpilot← Back to searchSign inGet full accessS Ehrström Gynmed AB
ABActiveOrg 5568804594Odengatan 62Medical specialists activities · NACE 8622Est. 20121-4 employees
Revenue 2024
SEK 1,3M
-29% vs 2023
EBITDA margin
1.6%
+120% vs 2023
Equity ratio
56.7%
Financial strength
Net profit 2024
SEK 5,9M
+4886% vs 2023
| Revenue | SEK 1,3M | -29% |
| EBITDA | SEK 21K | +120% |
| Net profit | SEK 5,9M | +4886% |
| Total assets | SEK 10,4M | +1156% |
| Equity | SEK 5,9M | +21025% |
| Employees | — | — |
Legal name
S Ehrström Gynmed AB
Org number
5568804594
Legal form
Aktiebolag
NACE code
8622 · Medical specialists activities
Founded
11 januari 2012
Share capital
SEK 50 000
Employees
1-4
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Företaget skall till största del bedriva medicinsk konsultation, undervisning, utveckling och forskning Därtill skall företaget även bedriva handel med värdepapper, författarskap, matcatering, interiör inredningskonsultation, samt design av smycken
Address
Odengatan 62
Email
sophia.ehrstrom@gmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 1 527 | 951 | 1 338 | 1 824 | 1 302 |
| Staff expenses | — | — | — | — | — |
| EBITDA | −210 | 624 | 63 | −107 | 21 |
| Depreciation & amort. | −2 | −0 | −0 | −0 | −0 |
| EBIT | −212 | 624 | 63 | −107 | 21 |
| Net financials | 87 | 26 | 3 | 12 | 5 865 |
| Profit before tax | −125 | 649 | 65 | −123 | 5 887 |
| Tax | −0 | −104 | −19 | −0 | −0 |
| Net profit | −125 | 545 | 46 | −123 | 5 887 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 687 | 975 | 548 | 831 | 10 439 |
| Equity | 75 | 620 | 96 | 28 | 5 915 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 611 | 355 | 451 | 803 | 4 525 |
| Total debt | 611 | 355 | 451 | 803 | 4 525 |
EBITDA margin
1.6%
This company
15.8%
Market median
-90% vs market
20202024
Equity ratio
56.7%
This company
38.2%
Market median
+48% vs market
20202024
Return on equity
99.5%
This company
18.4%
Market median
+441% vs market
20202024
Net profit margin
452.2%
This company
8.1%
Market median
+5483% vs market
20202024
Asset turnover
0.12×
This company
1.12×
Market median
-89% vs market
20202024
Debt / equity
0.76×
This company
0.62×
Market median
+23% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Deputy Board Member | 2022 | |
| Board of Directors | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of S Ehrström Gynmed AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Jan Peter Zetterström | Deputy Board Member | 0 companies |
| Sophia Magdalena Ehrström | Board of Directors | 0 companies |